P51 Randomised, single-centre, phase 2 trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer

Y.Chi; J.Wang; Z.Zheng; A.Zhou; L.Yang; T.Qu; W.Jiang; S.Shi; Y.Sun; Y.Song; S.Kang; J.Zheng

首页> 外文期刊>European Journal of Cancer Supplements >P51 Randomised, single-centre, phase 2 trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer

【24h】

P51 Randomised, single-centre, phase 2 trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer

机译：P51尼妥珠单抗联合顺铂和S-1作为晚期胃癌患者的一线治疗的随机，单中心，2期临床试验

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2011年第1期|共2页
作者
Y.Chi; J.Wang; Z.Zheng; A.Zhou; L.Yang; T.Qu; W.Jiang; S.Shi; Y.Sun; Y.Song; S.Kang; J.Zheng;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II) [J] . Nishikawa Kazuhiro, Tsuburaya Akira, Yoshikawa Takaki, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Capecitabine Plus顺铂的随机期II试验与S-1加顺铂作为晚期胃癌的一线治疗：Capecitabine Plus顺铂确定与S-1加上顺铂随机化PII试验（XParts II）
2. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II) [J] . Nishikawa Kazuhiro, Tsuburaya Akira, Yoshikawa Takaki, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Capecitabine Plus顺铂的随机期II试验与S-1加顺铂作为晚期胃癌的一线治疗：Capecitabine Plus顺铂确定与S-1加上顺铂随机化PII试验（XParts II）
3. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. [J] . Kang YK, Kang WK, Shin DB, Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第4期

机译：卡培他滨/顺铂与5-氟尿嘧啶/顺铂作为晚期胃癌患者的一线治疗方案：一项III期非劣效性随机试验。
4. S-1/CDDP/Lentinan Combination Chemotherapy for Inoperable Advanced Gastric Cancer [C] . Shoichi Nagahashi, Hidekazu Suzuki, Toshifumi Hib International Gastric Cancer Congress . 2005

机译：S-1 / CDDP / Lentinan组合化疗，可管理的胃癌无法操作
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 Plus Cisplatin as a Second-line Therapy and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report [O] . Yasushi Rino, Norio Yukawa, Hitoshi Murakami, 2010

机译：S-1单一疗法作为S-1加顺铂作为第二线疗法的一线联合疗法每周紫杉醇单一疗法作为三线疗法在晚期胃癌患者中的II期研究：第二份报告
7. P51 Randomised, single-centre, phase 2 trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer [O] . Chi Y., Wang J., Zheng Z., 2011

机译：P51尼妥珠单抗联合顺铂和S-1作为晚期胃癌患者的一线治疗的随机，单中心，2期临床试验

P51 Randomised, single-centre, phase 2 trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer

著录项

引文网络

相似文献

相关主题

期刊订阅